Faricimab▼ in neovascular age-related macular degeneration: updated week 48 efficacy, safety, and durability in the phase 3 TENAYA and LUCERNE trials

This presentation reports the pooled week 48 primary results from the phase 3 TENAYA and LUCERNE trials of faricimab▼ , a bispecific antibody that independently binds and neutralizes Ang-2 and VEGF-A, in patients with neovascular age-related macular degeneration. TENAYA and LUCERNE investigated the efficacy, safety, and durability of faricimab▼ , administered at individualized treatment intervals of up to every 16 weeks compared with aflibercept administered every 8 weeks.


Authors {{assetAuthors}}

Published date{{formattedPublishDate}}


Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.